Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team will be participating in two investment conferences in September.
Event: H.C. Wainwright 25 th Annual Global Investment Conference
Date: Tuesday, September 12, 2023
Time: 11:00 – 11:30 am ET
Event: Cantor 2023 Global Healthcare Conference
Date: Tuesday, September 26, 2023
Time: 9:10 – 9:40 am ET
Audio webcasts of these events will be available on the investor relations section of Evolus’ website at www.evolus.com . Replays of the webcasts will be available for 90 days after the date of each presentation.
About Evolus, Inc.
Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), globally licensed under the brand name Nuceiva ® . The product is manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, a line of five unique dermal fillers currently in late-stage development. Visit us at www.evolus.com , and follow us on LinkedIn , Twitter , Instagram or Facebook .
Jeuveau ® and Nuceiva ® are registered trademarks of Evolus, Inc.
Evolysse ™ is a trademark of Evolus, Inc.
Hi-Pure ™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230828748089/en/
Investor Contacts:
David K. Erickson
Vice President, Investor Relations
Tel: 949-966-1798
Email: david.erickson@evolus.com
Ned Mitchell
Arbor Advisory Group
Email: ir@evolus.com
Media Contact :
Email: media@evolus.com